Sortilin regulates hepatic exocytosis and endocytosis of ApoB containing lipoproteins (ApoB-Lp) and mediates the secretion of the subtilase PCSK9. To elucidate connections between these pathways, we previously identified a small molecule (cpd984) that binds to a non-canonical site on Sortilin. In hepatic cells cpd984 augments ApoB-Lp secretion, increases cellular PCSK9 levels, and reduces LDLR expression indicative of reduced secretion of PCSK9. We have shown that insulin-induced ApoB-Lp degradation occurs through Vps34-dependent autophagy. Here we show that the specific Vps34 inhibitor PIK-III enhances ApoB-100 secretion, reducing cellular levels of PCSK9 and Sortilin resulting in reduced LDLR expression, which implicates a role for autophagy in PCSK9 secretion. Results suggest that Sortilin is central to both PCSK9 and ApoB-100 secretion. Finally, we found that cpd984 in yeast blocks CPY secretion while increasing vacuolar homotypic fusion in a Vps10-dependent manner, indicating an evolutionarily conserved mechanism required for lysosomal protease trafficking.
INTRODUCTION
Trafficking pathways in yeast have been studied extensively as models of eukaryotic biology, which have in turn have been informative for discoveries in mammals related to human disease 1 . Vps10 in yeast traffics the lysosomal protease CPY (carboxypeptidase) from the Golgi to the vacuole in an anteretrograde fashion and Vps10 recycles back to the Golgi via the retromer.
Vps10 orthologue Sortilin in mammals traffics proteins from the Golgi where it is activated by furin mediated cleavage of its prodomain 2 . Sortilin is responsible for trafficking its ligands between secretory pathways and lysosomal protein pathways 3 . Vps10 and its mammalian counterpart Sortilin release cargo upon entering acidic endosomal compartments, which may be followed by dimerization of the luminal b-propeller domains of Sortilin. Subsequently, Vps10/Sortilin can be recycled back to the Golgi by the Retromer pathway, which could be mediated by dimerization 4 .
In higher eukaryotes, Sortilin is expressed in diverse cell types where it serves as a tissue specific cargo receptor. In neuronal cells, Sortilin participates in the secretion of neurotensin (NT) and other neuromodulators 5 , while in adipose tissue, Sortilin mediates the expression of the type 4 glucose transporter Glut4 at the plasma membrane 6 . In hepatic cells, the Sortilin receptor primarily regulates ApoB containing lipoproteins (Apo-Lp) and the protease PCSK9 (proprotein convertase subtilisin-kexin type 9). When secreted, PCSK9 binds to LDL receptor (LDLR), which targets both LDLR and PCSK9 for lysosomal degradation 7 .
Through GWAS analysis, SORT1 mutations have been identified as candidates that correlate mutations in Sortilin with cardiovascular disease outcomes 8, 9 . Sortilin has complex relationships with lipoprotein metabolism 10 and in lipid accumulation in arteries 11 . At the plasma membrane, Sortilin is found in Clathrin-coated pits similar to the LDLR, both of which bind ApoB-Lp 12 .
Differences in function and ligand specificity for the two receptors is unknown. Further complicating understanding of Sortilin function is its additional role in hepatic VLDL secretion where hepatic knockouts of Sortilin have been described to either increase or decrease VLDL secretion 13 . Sortilin is a multiligand receptor that can interact with the various ligands found on VLDL including B100 14 , ApoE 15, 16 , and PI(3,4,5)P 3 17 . Circulating VLDL content of PI(3,4,5)P 3 is enriched as compared to HDL and LDL 17 . The paradox for the ability of Sortilin to both increase or decrease VLDL secretion could relate to the relative concentration and position of ligands on the VLDL surface. Presence of PI(3,4,5)P 3 on lipoproteins relates to insulin signaling where PI(3,4,5)P 3 is considered as a principal mediator of insulin signal transduction, which could provide a mechanism for short-term modulation of VLDL interaction with Sortilin 18 19 .
An additional lipoprotein related ligand for Sortilin is the subtilase PCSK9, which has been shown by SPR to bind to human Sortilin with high affinity 20 . Importantly, this study showed that neurotensin (NT), a natural substrate for Sortilin, did not inhibit PCSK9 binding, even at saturating concentrations 21 . It has been proposed that PCSK9 is chaperoned for secretion by Sortilin. Once PCSK9 is released by sortilin extracellularly, it binds to LDLR resulting in degradation of the associated complex resulting in decreased expression of LDLR on the cell surface as LDLR bound to PCSK9 results in degradation of both PCSK9 and LDLR at the lysosome. We now show that PCSK9 secretion can be modulated by targeting Sortilin. We hypothesize that the relative secretion of Sortilin and PCSK9 can be co-regulated in hepatocytes by VLDL composition and by non-canonical binding of molecules to Site-2 of Sortilin. We suggest that this pathway is a complex and dynamic system for regulating ApoB-100 metabolism, which takes into account the balance of cellular intake (LDLR and VLDLR) and secretion of VLDL, a very low-density progenitor of LDL.
We further show that the non-canonical Site-2 of Sortilin. may have evolved from primitive systems for protease trafficking in yeast involving Vps10 with similarities for carboxypeptidase (CPY) and PCSK9 trafficking 22 .
Results presented suggest a potential alternative to current strategies targeting inhibition of the binding of PCSK9 to the LDL receptor (LDLR) 23 . We hypothesize that using Site-2 directed Sortilin binding molecules such as cpd984, hepatic LDLR expression and VLDL secretion could be increase under appropriate clinical settings. Furthermore, approaches could be developed to selectively regulate involved pathways by utilizing both sites of Sortilin, as we now show the inverse results of Site-1 and Site-2 specific Sortilin molecules 24 .
Results

Cpd984 and Cpd541 Bind at Different Locations of Human Sortilin
Our previous studies defined the interaction of cpd984 with Site-2 on Sortilin and its effects on NT binding and VLDL secretion 24 . Here we tested whether cpd984 in combination with cpd541, a
Site-1 directed small molecule could be used to examine the relationship between Sites-1 and -2 on Sortilin. In Figure 1A , we show SPR results of a titration of cpd984 concentrations binding to
Sortilin. This provides strong evidence that cpd984 binds Sortilin with high affinity, having a K D of 118 ± 38 nM ( Fig. 1A) . Next, we determined the binding affinity of Sortilin for cpd541, which we determined has a K D of 6.9 ± 1.1 µM for Sortilin ( Fig. 1B) . To determine whether binding Site-2 is independent of Site-1, we measured the binding of cpd984 in the presence of a nearly saturating concentration of 10 µM cpd541. We found that cpd984 bound to Sortilin with a similar affinity in the presence of 10 µM cpd541 as in the absence of cpd541 (Fig. 1C) . Results are consistent with our previous study showing that cpd984 bound Sortilin in the presence of C-terminal NT 17 .
Using ensemble molecular docking we showed that cpd984 binds to regions of Sortilin comprising
Site-2 ( Fig. 1D) , with a higher percentage than cpd541 (Fig. 1E ). Furthermore, we found that the protonated carboxylate on cpd541 did not affect its preferential clustering in Site-1 versus the more hydrophobic Site-2. In parallel, we found that cpd984 with an unprotonated pentaamine ring has a basic pH of 8.4 (± 1.2), as determined by ab initio calculations using Jaguar 25 . The protonation state of cpd984 had no effect on Site-2 binding, whereas cpd541 protonation state of the carboxylate resulted in a slight enrichment of cpd541 to Site 2 of Sortilin ( Fig. 1E) . To test whether pH dependent conformational changes impacted Site-1 or Site-2 binding, using Schrodinger Glide XP, we computationally docked both cpd541 and cpd984 in both Site-1 and
Site-2 of a crystal structure of Sortilin at neutral pH (PDB ID: 4PO7) and acidic pH (PDB ID: 6EHO) as shown in Figure 1F . Cpd541 showed dramatically reduced binding to Site-1 of Sortilin as compared to cpd984, indicating that cpd541 is similar to other Site-1 substrates that bind to the NT binding site of Sortilin, and lose affinity at low pH 26 . Furthermore, docking results confirm that cpd984 shows little discrimination between acidic and neutral pH structure of Sortilin.
Using molecular dynamics (MD), six 50 ns simulations were run for cpd541 and cpd984 for both
Sites-1 and -2 comprising 24 simulations over 1 microsecond in total ( Fig. 2A) . The three best binding poses of cpd984 to Site-1 were chosen using ensemble poses generated from clusters of Site-1, whereas the three best poses with a salt bridge from cpd541 to Arg292 with the best autodock docking score were chosen and all three poses run in duplicate Figure 1D . For Site-2, the cpd984 pose comprising the closest match to our previously determined pose of cpd984 to Site-2 was used, whereas for cpd541 the three best poses of cpd541 to Site 2 were chosen 24 .
Results and analysis of the MD simulations are presented in Figure 2 . Cpd984 ( Fig. 2A) and cpd541 ( Fig. 2D ) average distances from Arg292 in Site-1 and Leu539 in Site-2 are given. We found that cpd984 remained within 10 Å from Leu539 throughout the simulation (Fig 2A) 24 . In contrast, simulations of cpd984 to Site-1 showed that it did not stay within 10 Å of R292 for Site-1. In addition to the stable association of cpd984 with Site-2, we found that cpd984 buries itself into the hydrophobic Sortilin beta propeller, between blades 1 and 10. Using F555 as a reference amino acid nearing the end of blade 10 of Sortilin, we show that cpd984 on average over six 50
ns simulations comes closer to this hydrophobic cavity over time ( Fig. 2B) . A representative endpoint of one of these simulations is presented in a ligand interaction diagram of cpd984 is presented in Figure 2C . Taken together, we hypothesize that the hydrophobic cpd984 is more likely to stay bound to Site-2 than to Site-1. Additionally, as cpd984 does not carry a negative charge at acidic or neutral pH, and has greater association with Site-2 than Site-1 of Sortilin, it is likely that cpd984 binding to Sortilin is pH independent in the cell (Fig. 1E, F) .
Regarding cpd541, we hypothesized that it requires some electrostatic binding to form a salt bridge with Arg292 and stably interact with Site-1 via its carboxylate. In Figure 2D , we found that cpd541 did not stay as tightly associated to Site-2 of Sortilin as compared cpd984. In contrast, cpd541 stably associated with Site-1 more than Site-2. That said, not all cpd541 simulations remained associated with R292. A fraction of cpd541 simulations started with a salt bridge to Arg292, eventually stably forming a salt bridge with Lys227 as depicted in Figure 2F of Sortilin, and that cpd541 had a greater fraction time bound than cpd541 to Site-1 ( Fig. 2E) .
Furthermore, the residues of interest for these interactions corresponded well to the NT peptide binding modes of Sortilin from PDB ID: 4PO7, which we have hypothesized represents the full NT peptide across the Sortilin cavity connecting Site-1 and Site-2 of Sortilin 24 .
Sortilin-targeting Small Molecule alters NT Binding and ApoB Secretion
Using SPR to monitor NT binding to Sortilin we found that cpd541 competed for NT binding to Sortilin in a dose dependent fashion (Fig. 3A) . In contrast, we now show that cpd984 enhanced NT binding to Sortilin in a dose dependent fashion 24 . As NT binding has been shown to be mainly guided by Site-1, we hypothesize that cpd541 as an inhibitor most likely binds to NT binding Site- 
The Vps34-Specific Inhibitor PIK-III blocks Autophagy and Sortilin Function
Previous studies of Sortilin indicate a specialized autophagy responsible for insulin-dependent degradation of ApoB in a manner independent of p62 28, 29 . To test effects of Vps34 specific effects on trafficking regulation of VLDL and LDLR we used the Vps34-specific inhibitor PIK-III in lieu of pan-PI 3-Kinase inhibitors such as wortmannin 30 . In order to determine efficacy of PIKIII on autophagy as a control, we measured the autophagy markers LC3-I, LC3-II, and p62 in the presence or absence of wortmannin or PIKIII. Basal autophagic flux was blocked with E/P (E-64d
and Pepstatin) 31, 32 , or HCQ (hydroxychloroquine) 33, 34 , or left untreated. Autophagy activation was detected by presence or absence of LC3-II. We found that LC3-II production was inhibited completely under all three conditions with PIK-III, whereas wortmannin had no effect (Fig. 4A ).
Furthermore, it appears that neither PIK-III nor wortmannin affected p62 levels under autophagic conditions similar to a previous report suggesting a selective form of autophagy associated with Sortilin 28 . As a measure of insulin-triggered autophagy, we tested whether PIK-III had an effect on the phospho-AKT pathway. We found that PIK-III, unlike wortmannin, failed to inhibit phospho-AKT production ( Fig. 4B) .
PIK-III Alters PCSK9 Secretion and LDLR Surface Expression
After characterizing PIKIII as an autophagy inhibitor, we tested for its effects on Sortilin mediated trafficking by monitoring both VLDL secretion and PCSK9 regulation of LDLR in the presence and absence of wortmannin and PIKIII. Our results indicate that PIK-III affected both VLDL secretion ( Fig. 4C ) and LDLR expression ( Fig. 4D ). It appears from Figure 4C that total ApoB increased with PIKIII in both the cell and the media. We hypothesize that as PIKIII inhibits autophagic degradation of ApoB, it would then increase the total amount of ApoB available, therefore, we would expect more ApoB shifted towards secretion while the intracellular increase in ApoB was due to lack of autophagic degradation. Immunoblotting for intracellular pools of PCSK9, Sortilin, and LDLR showed a decrease in LDLR expression, and reduced levels of Sortilin and PCSK9 ( Fig. 4D) . We hypothesize that decreased intracellular PCSK9 is consistent with increased PCSK9 secretion, resulting in decreased LDLR expression. The decreased intracellular Sortilin is likely due to the requirement for more Sortilin to be diverted to secretion due to increased ApoB availability.
Effect of cpd541 and cpd984 on the Sortilin-VLDL-PCSK9 Trafficking Pathway.
We further tested the effect of modulating Sortilin trafficking through defined Site-1 and Site-2 molecules. We found that the Site-2 cpd984 enhanced LDLR expression ( Fig. 5A ), whereas cpd541 had little effect on PCSK9. We hypothesized that PCSK9 binds to Site-2, which could explain why cpd984 was effective in modulating PCSK9 as opposed to cpd541. Using the proteinprotein docking prediction software ClusPro, we docked PDB ID: 4PO7 Sortilin to PDB ID: 2P4E PCSK9, removing the NT fragments of 4PO7 prior to simulation. All 10 clusters showed PCSK9 binding to Blade-1 of Sortilin (Fig. 5B) , and selected the top 3 poses with the lowest overall predicted DG. We ran the three generated clusters for 25 ns each and analyzed both Sortilin and PCSK9 contact points for binding approximated by having a distance of less than 3.5 Angstroms between the two proteins. This showed that the residues of Sortilin closest to PCSK9 over throughout multiple trajectories remained to be adjacent to Site-2 or on the outside of the Sortilin cavity opposite Site-2. In Figure 5D , we show a root-mean-squared fluctuation (RMSF) analysis of these same trajectories for Sortilin. Residue analysis (Fig. 5C) , and RMSF analysis ( Fig. 5E) were additionally performed for PCSK9 using residues at its interface with LDLR for reference utilizing a 5 ns MD simulation of PCSK9 to LDLR from PDB ID: 3P5C. All results are consistent with PCSK9 binding to Site-2.
Characterization of VLDL and LDL Sortilin Affinity
Having concluded previously that PI(3,4,5)P 3 binds to Site-1 17 , we tested in vitro binding using SPR to determine the effect of cpd541 and cpd984 on Sortilin binding of PI(3,4,5)P 3 . First, we found that diC8-PI(3,4,5)P 3 bound with high affinity to crosslinked Sortilin with a K D of 4.2 µM ± 380 nM ( Fig. 6A) . When we ran the same diC8-PI(3,4,5)P 3 concentration curves in the presence of 10 µM cpd541 and 10 µM cpd984, we found that cpd541 abolished PI(3,4,5)P 3 We previously showed that circulating VLDL contains more PI(3,4,5)P 3 than LDL 17 . Using these same fractions, we characterized rat derived circulating VLDL and LDL binding to Sortilin using SPR and MST. Here we show that rat VLDL bound Sortilin with a K D of ~4 nM, an order of magnitude higher relative to binding LDL with a K D of 54-74 nM. We hypothesize that this was due to differences in particle composition, where VLDL acquired PI(3,4,5)P 3 during the cosynthesis with ApoB. (Fig. 6D, E) . These data suggest the differences between LDL and VLDL binding was independent of ApoB, as both particle types contain the protein, suggesting a primary difference was the presence of PI(3,4,5)P 3 .
Sortilin Small Molecule Effect in Yeast
The yeast gene VPS10 encodes the type I transmembrane receptor for carboxypeptidase Y (CPY) that cycles between the late Golgi and the prevacuolar compartment 22, 35 . The CPY hydrolase enters the ER as an inactive zymogen and is modified by four N-linked polysaccharides forming p1CPY (67 kDa) 36 . Thereafter, p1CPY transits through the Golgi where polysaccharides are extended to form the p2CPY precursor (69 kDa). p2CPY is transported from late Golgi in vesicles containing the subtilase Kex2, and is subsequently delivered to the vacuole. Upon arrival, the amino pro-segment of p2CPY is cleaved to yield enzymatically active mature CPY or mCPY (61 kDa). Similar to Sortilin, Vps10 has been shown to have multiple binding sites for different ligands in yeast, however, unlike Sortilin, Vps10 contains two protein sorting domains making Vps10 substantially larger than human Sortilin. 37 We hypothesized that Sortilin trafficking of PCSK9 should share consistencies with Vps10 sorting of CPY, reasoning that the mechanism for regulation of trafficking of proteases destined for the lysosome or vacuole could help elucidate Sortilin cellular itinerary for other ligands such as VLDL-ApoB. First, we deleted VPS10 from our fusion tester yeast strains DKY6281 and BJ3505 and compared vacuolar levels of CPY and the late endosomal/lysosomal rab GTPase Ypt7. In Figure   7A we show immunoblots of isolated vacuoles from vps10D yeast and their parent strains. These results indicate that CPY at the vacuole was reduced in the absence of Vps10 in both strains.
Like PCSK9, we assume that increases in CPY at the vacuole, correspond with decreases in secretion of CPY. We used a classical technique to characterize trafficking defects in response to cpd984 38 . To test if a Site-2 homologous area was present on Vps10, we treated wild type yeast cells with cpd984 and measured CPY secretion. We found that cells treated with 20 µM cpd984 accumulated substantially more CPY at the yeast vacuole relative to the untreated control ( Fig. 7B) . To test whether the increase in vacuolar CPY correlated to a decrease in secreted CPY stores, we treated individual yeast cultures with a concentration curve of cpd984. As shown in Figure 7C , secreted CPY was reduced with increased cpd984 concentrations. Together these data showed that a Site-2-like domain may be present on Vps10.
Finally, we hypothesized that altered trafficking to the vacuole via Vps10 increases in vacuolar CPY due to cpd984 could alter vacuolar homotypic fusion as a measure for increased trafficking to lysosomes. In vitro vacuole fusion assays showed that cpd984 administration resulted in dose dependent increases in fusion of WT vacuoles, while no effect was seen with vps10D vacuoles, suggesting that proteins responsible for changes in fusogenicity may depend on Vps10 (Fig. 7D ).
This lends support to a hypothesis that cpd984 enhances Vps34 recruitment resulting in increased trafficking to the lysosome as a potential mechanism.
Discussion
The endocytic pathway for ApoB-Lp uptake by LDLR in hepatocytes has been studied extensively and forms much of the basis for current therapies controlling high LDL cholesterol in humans 39 .
Little is known about the role of Sortilin in this process or how the relative concentrations of these receptors are regulated by Sortilin in this pathway 7, 10 . In this study we undertook to further examine the role of Sortilin in LDL/VLDL trafficking. These data show that Sortilin binds VLDL with higher affinity compared to LDL (Fig. 6C, D) . We speculate this to be the result of increased ligands for Sortilin on the VLDL surface other than ApoB-100, e.g. PI(3,4,5)P 3 or ApoE, in contrast to decreased alternative ligands for LDL other than ApoB-100 17, 40 .
Considering that PCSK9 is an additional ligand for Sortilin-mediated secretion in hepatocytes 7 , we further explored the effect of cpd984 on PCSK9 binding to Sortilin. Using functional endpoints in McA cells we demonstrated that cpd984 treated cells retained PCSK9 ( Fig. 5A) resulting in increased expression of LDLR. The absence of these effects with the Site-1 ligand cpd541
suggests Site-2 mediates this function. These results are consistent with the hypothesis that Site-2 is the primary region of Sortilin for PCSK9 in chaperoning its secretion. Furthermore, we showed that VLDL secretion is inversely modulated by administration of these two compounds (Fig. 3C) , that both cpd effects depend on Sortilin expression levels (Fig. 3B) , and that when both sites are occupied effects on VLDL secretion are attenuated (Fig. 3C) . This indicates the potential for site specific modulation of sortilin chaperone activity.
Regarding NT binding to Sortilin, we showed that cpd541 inhibits NT binding whereas cpd984 enhances binding (Fig. 3A) . Results suggest a potential allosteric effect of Site-2 binding on VLDL binding to Site-1, resulting in increased secretion (Fig. 3B, C) . Sortilin plays a central role in hepatic ApoB-Lp metabolism, yet its exact role remains enigmatic 13 . The questions that remain are: 1) How do Sortilin knockdowns both increase and decrease hepatic VLDL secretion? 10 Considering the complexity of these questions, we propose a model where Sortilin contains at least two interactive sites for ligand binding.
In addition to mediating ApoB-Lp secretion, Sortilin has a significant role in ApoB degradation by the lysosome 41 . Our previous work showed that blocking autophagy prevents insulin signaling from suppressing ApoB secretion. Whether insulin dependent autophagy is merely an accumulation of basal autophagy is unknown, however insulin-dependent PI(3,4,5)P 3 production its incorporation into VLDL leads us to posit that the production of this lipid diverts ApoB-Lp to the autophagic pathway. We further demonstrated that autophagy regulates PCSK9, Sortilin and LDLR levels (Fig. 4C, D) . This process is not dependent on the production of pAKT triggered by insulin, as PIK-III failed to block AKT phosphorylation (Fig. 4B) 30 . The reduction in LDLR, Sortilin and PCSK9 in the presence of PIK-III suggests that loss of autophagy results in increased secretion of Sortilin and PCSK9 with resultant PCSK9-mediated reduction in LDLR. Results suggest loss of autophagy affects Sortilin related processes involving both Site-2 and Site-1.
Considering the importance of Site-2 in hepatic ApoB-Lp metabolism, we speculated that the Site-2 related pathways for PCSK9 and ApoB-Lp may be conserved in other cell types with some probability that it could have evolved from a primitive pathway present in yeast. The mechanistic role of the yeast CPY protease receptor Vps10, the ancestor of Sortilin, is well well-documented, and also involves at least two ligand binding domains 42 . We used cpd984 to ask whether it might modulate CPY trafficking as it had with Sortilin with respect to the protease PCSK9. Indeed, treating yeast with cpd984 resulted in decreased CPY secretion while increasing its intracellular pool, suggesting CPY sorting is a parallel pathway to PCSK9 sorting as shown by its accumulation at the vacuole and decrease extracellularly ( Fig. 7B, C ). It appears that these effects are Vps10 dependent as fusion increases with cpd984 were attenuated in vps10D strains (Fig. 7D) .
These studies demonstrate a complex interconnected regulatory system for hepatic lipoprotein metabolism based on evolution of Vps10. Considerable research will be required to completely define this mode of regulation. Considering the complexity of this system, we believe that our observations on Sortilin regulation in hepatocytes and yeast may serve as a paradigm for Sortilin trafficking in other cell types such as neuronal and adipose. Implications of these studies may also have impact on understanding other Sortilin related processes including insulin secretion 8, 24, 43 , Glut4 transport [44] [45] [46] [47] , and plaque formation in Alzheimer's [48] [49] [50] as well as serving as a model for function of other Vps10 homologues such as Vth1, Vth2, and YN94 or Sortilin homologues such as SORCS and SORLA involved in similar processes as Sortilin. Understanding and delineating these protein functions should improve our understanding of the complex regulation of proteins involved in Vps10 family sorting pathways 51, 52 . 
Methods
Cell culture, materials and reagents
Cell Culture
Rat hepatocytes (RH) were isolated from Sprague-Dawley rat livers, and were cultured on collagen-coated dishes in Waymouth's 751/1 medium containing 0.2% (w/v) BSA as described previously 56 . Wild-type McA cells were maintained in culture in complete DMEM (cDMEM) 53 .
Inhibitors were used at reported concentrations for cpd984 and cpd541. PIK-III was administered at 1 µM and wortmannin administered 10 µM. Inhibitors were validated in RH where cell toxicity was minimal as determined by LDH release.
Knockdown of Sortilin in McA cells using siRNA
McA cells were transfected using Fugene6 according to manufacturer's protocol (Promega Corp., Madison WI) using three different pGIPZ based vectors expressing shRNAi targeting rat Sort1 mRNA (V2LMM_58553, V3LMM_450660, V3LMM_450662), and one scrambled, non-silencing control (GE Healthcare Dharmacon, Lafayette, CO) as previously described 24 . Puromycin selection was performed on McA cells. Sortilin knockdown (KD) from each cell line was examined by immunoblotting.
Immunoblotting
McA cell lysates were prepared and denatured proteins were separated by SDS-PAGE as described previously 43 
Immuno-slot blotting
VLDL and LDL preparations for SPR and MST in Figure 5 were prepared as previously described 24 . Experimental media were adjusted to 1% (v/v) protease inhibitor cocktail I (EMD Millipore) and
to a salt density of 1.019 g/ml by addition of a solution of NaBr (d = 1.495 g/ml). VLDL was isolated by ultracentrifugation in a L-70 Ultracentrifuge (Beckman Coulter, Inc., Fullterton, CA) using a 50Ti rotor (200,000 x g, 18 h, 14°C). Following centrifugation, the top 1.5 -2.0 ml VLDL fraction was removed using a syringe and weighed to determine volume. VLDL samples were applied in triplicate wells (0.2 to 0.4 ml per well) in a Bio-Dot® SF apparatus (Bio-Rad). Two PVDF membranes were used together for blotting: the top was Immobilon-P (IPVH09120 SF) and the bottom was Immobilon-PSQ (ISEQ09120 SF); both were obtained from EMD Millipore. VLDL-ApoB standards were prepared from rat plasma VLDL and total ApoB (B100 and B48) and B100 content were determined on stained gels following SDS-PAGE separation 57 . VLDL-ApoB standards in TBS were slotted in duplicate alongside test samples. After filtration, 0.4 ml of TBS was added as a wash. After final filtration, membranes were air dried, rehydrated in methanol and incubated in TBS then in blocking buffer at 4ºC overnight. At this stage slot blots were evaluated similarly to immunoblotting. After chemiluminescence development and B100 quantitation, slot blots were stripped by incubation in Restore™ PLUS (ThermoFisher) for 15 min at room temperature and were reblocked overnight at 4°C. Total ApoB (B100 and B48) present in VLDL was then evaluated following incubation with rabbit polyclonal anti-rat ApoB. The bottom PVDF membrane was carried through the entire procedure to assure there was no "bleed through" of test samples. VLDL-ApoB and VLDL-B100 content were calculated from standard curves generated by VLDL-ApoB standards. Recovery of rat VLDL added to unspent media averaged 94% ± 4.9% with a CV of 5.2% (n = 6 replicates). 
Computational modeling and compound screening
MD Simulations of apo and holo Sortilin
Using the aforementioned crystal structure of Sortilin (PDB ID:4PO7) molecular dynamics simulations were done using NAMD 2.12 59 using the CHARMM36m force field 60 . Prior simulating, the system was prepared using the CHARMM-GUI solution builder, with a salt concentration of 150 mM NaCl. Simulation parameters included constant pressure of 1 atm via Langevin dynamics, as well as a constant temperature of 310 K using Langevin piston Nosé−Hoover methods 61, 62 . Long-range electrostatic forces were evaluated using the particle mesh Ewald (PME) with a 1 Å grid spacing 63, 64 . Van der Waals interactions were calculated using a 12 Å cutoff with a force-based switching scheme after 10 Å, as well as a 2 fs time step integration via the SETTLE algorithm 65 . Visualization and analysis was done using VMD 1.9.3 66 . The system was equilibrated for 20 ns restraining the Cα atoms of the protein (1.0 kcal/mol/Å 2 ) to allow for solvation. This was followed by a production run of 50 ns without restraints for 4 poses taken from ensemble docking, 3 poses with the highest affinity pose for Site-1 of Sortilin run in duplicate for each, and the pose for Site-2 that represented the predicted pose as shown previously 17 .
Ensemble Molecular Docking of cpd541 and cpd984
To probe cpd541 and cpd984 interactions with Sortilin, ensemble molecular docking was employed as described 67 . Using snapshots from the 50 ns production simulation to sample protein dynamics, snapshots were taken every 200 ps. Each of the resultant 250 snapshots were used to dock cpd541 and cpd984 using a 100Å by 90Å by 70Å grid box. Docking was done with an exhaustiveness of 10, yielding a total of 2500 docked poses. Resultant poses were clustered using a hybrid K-centers/K-medoids algorithm, utilizing an RMSD method 68, 69 . Representative poses with highest scoring affinities in clusters closest to Site-1 and Site-2 were selected for further 50 ns simulations. The resultant drug bound simulations were analyzed with VMD as well as MDAnalysis 70, 71 .
Protein-Protein Docking and Simulations
Characterization of protein-protein interactions between Sortilin (PDB:4PO7) and PCSK9
(PDB:2P4E) was done using the default settings of webserver ClusPro [71] [72] [73] 
Microscale Thermophoresis
Thermophoresis measurements were performed using a Monolith NT.115 labeled thermophoresis instrument 72, 73 . Sortilin-His6 was labeled with Ni-NTA Atto-488 according to the manufacturer's protocol as previously described 73, 74 curves were fit using a specific binding equation with hill slope, whereas all other SPR saturation curves were fit using a 1:1 specific binding model.
Vacuole Isolation and in vitro vacuole fusion assay
Vacuoles were isolated from BJ3505 75 and DKY6281 76 , which were used for fusion assays by density gradient floatation as previously described 72 
Yeast Western Analysis and CPY Secretion
Vacuoles of BJ3505, DK6281, and their vps10D derivatives were isolated and vacuoles were removed by centrifugation (16, 
